- Trial phase
- Approved
- Time to market
- Already approved and commercially available since September 2014.
- Why 4/10
- Auryxia is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst is the Q4 2026 earnings report (expected early March 2027) showing the pace of generic erosion, but quarterly sales are not a binary catalyst. ImpactScore is 4 because the drug is an approved, revenue-generating product in decline with no upcoming binary event.
Auryxia has no upcoming binary catalyst; its revenue trajectory is a steady decline driven by Teva's generic entry in March 2026. The next meaningful event for Akebia as a whole is the January 2027 expiration of Vafseo's TDAPA transitional add-on payment, which could pressure Vafseo pricing. Investors should watch Q4 2026 Auryxia revenue (expected in early March 2027) to gauge the pace of generic erosion.
Price Chart
Executive Summary
Auryxia (ferric citrate) is an FDA-approved oral phosphate binder and iron replacement therapy for chronic kidney disease patients, originally approved in 2014 and expanded to a second indication in 2017. The drug is now in commercial decline: Teva launched a generic version in March 2026, and Auryxia's quarterly net revenue has fallen from $42.5 million (Q3 2025) to $20.0 million (Q3 2026). Akebia Therapeutics is pivoting its commercial focus to Vafseo (vadadustat), a newer anemia drug for dialysis patients. For an investor, Auryxia is a mature, declining asset with no upcoming binary catalyst; the stock's thesis increasingly depends on Vafseo's commercial trajectory rather than Auryxia.
How It Works
Auryxia (ferric citrate) is an oral iron-based tablet that works as a phosphate binder. In the stomach, it binds to phosphorus from food, preventing it from being absorbed into the bloodstream and allowing it to exit the body through waste. This lowers serum phosphorus levels in kidney dialysis patients. Separately, the iron in the drug can be absorbed to treat iron deficiency anemia in chronic kidney disease patients not on dialysis.
Trial Status
Auryxia is FDA-approved and commercially marketed. No active clinical trials are required for this drug; Akebia's pipeline focus has shifted to Vafseo (vadadustat) and rare kidney disease assets.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings report (expected early March 2027) showing the pace of Auryxia generic erosion
- January 2027 expiration of Vafseo's TDAPA add-on payment, which could affect combined product revenue dynamics
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Akebia Therapeutics, Inc. PRESS-RELEASE AKBA ·Originating report